{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T18:57:33Z","timestamp":1768676253664,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Health","award":["R01-CA228157S"],"award-info":[{"award-number":["R01-CA228157S"]}]},{"name":"National Institute of Health","award":["R21-CA220475"],"award-info":[{"award-number":["R21-CA220475"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1-CA121947"],"award-info":[{"award-number":["UM1-CA121947"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011075","name":"David Geffen School of Medicine, University of California, Los Angeles","doi-asserted-by":"publisher","award":["Pendleton Charitable Trust"],"award-info":[{"award-number":["Pendleton Charitable Trust"]}],"id":[{"id":"10.13039\/100011075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Emerging evidence shows that tumor cells secrete extracellular vesicles (EVs) that carry bioactive cell surface markers, such as programmed death-ligand 1 (PD-L1), which can modulate immune responses and inhibit anti-tumor responses, potentially playing a role in lymphomagenesis and in promoting the growth of these cancers. In this study, we investigated the role of EVs expressing cell surface molecules associated with B cell activation and immune regulation. We measured levels of EVs derived from plasma from 57 subjects with AIDS-related non-Hodgkin lymphoma (AIDS-NHL) enrolled in the AIDS Malignancies Consortium (AMC) 034 clinical trial at baseline and post-treatment with rituximab plus concurrent infusional EPOCH chemotherapy. We found that plasma levels of EVs expressing PD-L1, CD40, CD40L or TNF-RII were significantly reduced after cancer treatment. AIDS-NHL patients with the diffuse large B cell lymphoma (DLBCL) tumor subtype had decreased plasma levels of EVs bearing PD-L1, compared to those with Burkitt\u2019s lymphoma. CD40, CD40L and TNF-RII-expressing EVs showed a significant positive correlation with plasma levels of IL-10, CXCL13, sCD25, sTNF-RII and IL-18. Our results suggest that patients with AIDS-NHL have higher levels of EVs expressing PD-L1, CD40, CD40L or TNF-RII in circulation before cancer treatment and that levels of these EVs are associated with levels of biomarkers of microbial translocation and inflammation.<\/jats:p>","DOI":"10.1038\/s41598-022-13101-8","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T10:06:52Z","timestamp":1654164412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Plasma extracellular vesicles bearing PD-L1, CD40, CD40L or TNF-RII are significantly reduced after treatment of AIDS-NHL"],"prefix":"10.1038","volume":"12","author":[{"given":"Laura E.","family":"Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelly","family":"Lensing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry I.","family":"Magpantay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Mitsuyasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard F.","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otoniel","family":"Mart\u00ednez-Maza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Epeldegui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"13101_CR1","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1097\/00002030-200108170-00005","volume":"15","author":"A Antinori","year":"2001","unstructured":"Antinori, A. et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 15, 1483\u20131491. https:\/\/doi.org\/10.1097\/00002030-200108170-00005 (2001).","journal-title":"AIDS"},{"key":"13101_CR2","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1182\/blood.v98.8.2339","volume":"98","author":"C Besson","year":"2001","unstructured":"Besson, C. et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 98, 2339\u20132344. https:\/\/doi.org\/10.1182\/blood.v98.8.2339 (2001).","journal-title":"Blood"},{"key":"13101_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/00002030-200301030-00011","volume":"17","author":"L Gerard","year":"2003","unstructured":"Gerard, L. et al. Improved survival in HIV-related Hodgkin\u2019s lymphoma since the introduction of highly active antiretroviral therapy. AIDS 17, 81\u201387. https:\/\/doi.org\/10.1097\/00002030-200301030-00011 (2003).","journal-title":"AIDS"},{"key":"13101_CR4","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1097\/00002030-200307040-00013","volume":"17","author":"C Hoffmann","year":"2003","unstructured":"Hoffmann, C. et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 17, 1521\u20131529. https:\/\/doi.org\/10.1097\/00002030-200307040-00013 (2003).","journal-title":"AIDS"},{"key":"13101_CR5","first-page":"439","volume":"15","author":"RJ Biggar","year":"2001","unstructured":"Biggar, R. J. AIDS-related cancers in the era of highly active antiretroviral therapy. Oncology (Williston Park) 15, 439\u2013448 (2001) (discussion 448\u2013439).","journal-title":"Oncology (Williston Park)"},{"key":"13101_CR6","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1097\/01.aids.0000238411.75324.59","volume":"20","author":"EA Engels","year":"2006","unstructured":"Engels, E. A. et al. Trends in cancer risk among people with AIDS in the United States 1980\u20132002. AIDS 20, 1645\u20131654. https:\/\/doi.org\/10.1097\/01.aids.0000238411.75324.59 (2006).","journal-title":"AIDS"},{"key":"13101_CR7","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1097\/00126334-200408010-00013","volume":"36","author":"NA Hessol","year":"2004","unstructured":"Hessol, N. A. et al. Cancer risk among participants in the women\u2019s interagency HIV study. J. Acquir. Immune Defic. Syndr. 36, 978\u2013985. https:\/\/doi.org\/10.1097\/00126334-200408010-00013 (2004).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"13101_CR8","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1002\/cncr.25530","volume":"116","author":"EC Seaberg","year":"2010","unstructured":"Seaberg, E. C. et al. Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer 116, 5507\u20135516. https:\/\/doi.org\/10.1002\/cncr.25530 (2010).","journal-title":"Cancer"},{"key":"13101_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1086\/499054","volume":"42","author":"F Bonnet","year":"2006","unstructured":"Bonnet, F. et al. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France. Clin. Infect. Dis. 42, 411\u2013417. https:\/\/doi.org\/10.1086\/499054 (2006).","journal-title":"Clin. Infect. Dis."},{"key":"13101_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/cncr.20354","volume":"101","author":"F Bonnet","year":"2004","unstructured":"Bonnet, F. et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer 101, 317\u2013324. https:\/\/doi.org\/10.1002\/cncr.20354 (2004).","journal-title":"Cancer"},{"key":"13101_CR11","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","volume":"84","author":"DG Maloney","year":"1994","unstructured":"Maloney, D. G. et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84, 2457\u20132466 (1994).","journal-title":"Blood"},{"key":"13101_CR12","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1002\/cncr.26723","volume":"118","author":"SK Barta","year":"2012","unstructured":"Barta, S. K., Lee, J. Y., Kaplan, L. D., Noy, A. & Sparano, J. A. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer 118, 3977\u20133983. https:\/\/doi.org\/10.1002\/cncr.26723 (2012).","journal-title":"Cancer"},{"key":"13101_CR13","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","volume":"115","author":"JA Sparano","year":"2010","unstructured":"Sparano, J. A. et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 115, 3008\u20133016. https:\/\/doi.org\/10.1182\/blood-2009-08-231613 (2010).","journal-title":"Blood"},{"key":"13101_CR14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243386","author":"JA Sparano","year":"2020","unstructured":"Sparano, J. A. et al. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin\u2019s lymphoma. Haematologica https:\/\/doi.org\/10.3324\/haematol.2019.243386 (2020).","journal-title":"Haematologica"},{"key":"13101_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186549","volume":"12","author":"A Cingolani","year":"2017","unstructured":"Cingolani, A. et al. Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. PLoS\u00a0One 12, e0186549. https:\/\/doi.org\/10.1371\/journal.pone.0186549 (2017).","journal-title":"PLoS\u00a0One"},{"key":"13101_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1158\/1078-0432.CCR-14-0466","volume":"22","author":"M Epeldegui","year":"2016","unstructured":"Epeldegui, M. et al. Predictive value of cytokines and immune activation biomarkers in AIDS-related non-Hodgkin lymphoma treated with rituximab plus infusional EPOCH (AMC-034 trial). Clin. Cancer Res. 22, 328\u2013336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0466 (2016).","journal-title":"Clin. Cancer Res."},{"key":"13101_CR17","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-20-4167","volume":"27","author":"LE Martinez","year":"2021","unstructured":"Martinez, L. E. et al. Immune activation and microbial translocation as prognostic biomarkers for AIDS-related non-Hodgkin lymphoma in the AMC-034 study. Clin. Cancer Res. 27, 4642\u20134651. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4167 (2021).","journal-title":"Clin. Cancer Res."},{"key":"13101_CR18","doi-asserted-by":"publisher","first-page":"9371","DOI":"10.1038\/s41598-019-45479-3","volume":"9","author":"M Epeldegui","year":"2019","unstructured":"Epeldegui, M. et al. Elevated numbers of PD-L1 expressing B cells are associated with the development of AIDS-NHL. Sci. Rep. 9, 9371. https:\/\/doi.org\/10.1038\/s41598-019-45479-3 (2019).","journal-title":"Sci. Rep."},{"key":"13101_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321\u2013330. https:\/\/doi.org\/10.1038\/nature21349 (2017).","journal-title":"Nature"},{"key":"13101_CR20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847\u2013856. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0983 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"13101_CR21","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774 (2016).","journal-title":"N. Engl. J. Med."},{"key":"13101_CR22","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571. https:\/\/doi.org\/10.1038\/nature13954 (2014).","journal-title":"Nature"},{"key":"13101_CR23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1146\/annurev-biochem-013118-111902","volume":"88","author":"DM Pegtel","year":"2019","unstructured":"Pegtel, D. M. & Gould, S. J. Exosomes. Annu. Rev. Biochem. 88, 487\u2013514. https:\/\/doi.org\/10.1146\/annurev-biochem-013118-111902 (2019).","journal-title":"Annu. Rev. Biochem."},{"key":"13101_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12943-019-0995-1","volume":"18","author":"Y Guo","year":"2019","unstructured":"Guo, Y. et al. Effects of exosomes on pre-metastatic niche formation in tumors. Mol. Cancer 18, 39. https:\/\/doi.org\/10.1186\/s12943-019-0995-1 (2019).","journal-title":"Mol. Cancer"},{"key":"13101_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-019-0264-y","volume":"20","author":"D Daassi","year":"2020","unstructured":"Daassi, D., Mahoney, K. M. & Freeman, G. J. The importance of exosomal PDL1 in tumour immune evasion. Nat. Rev. Immunol. 20, 209\u2013215. https:\/\/doi.org\/10.1038\/s41577-019-0264-y (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"13101_CR26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12943-019-1074-3","volume":"18","author":"F Xie","year":"2019","unstructured":"Xie, F., Xu, M., Lu, J., Mao, L. & Wang, S. The role of exosomal PD-L1 in tumor progression and immunotherapy. Mol. Cancer 18, 146. https:\/\/doi.org\/10.1186\/s12943-019-1074-3 (2019).","journal-title":"Mol. Cancer"},{"key":"13101_CR27","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/1724600819884722","volume":"34","author":"SW Chen","year":"2019","unstructured":"Chen, S. W. et al. Expression of PD-1\/PD-L1 in head and neck squamous cell carcinoma and its clinical significance. Int. J. Biol. Mark. 34, 398\u2013405. https:\/\/doi.org\/10.1177\/1724600819884722 (2019).","journal-title":"Int. J. Biol. Mark."},{"key":"13101_CR28","doi-asserted-by":"publisher","first-page":"eaar2766","DOI":"10.1126\/sciadv.aar2766","volume":"4","author":"FL Ricklefs","year":"2018","unstructured":"Ricklefs, F. L. et al. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci. Adv. 4, eaar2766. https:\/\/doi.org\/10.1126\/sciadv.aar2766 (2018).","journal-title":"Sci. Adv."},{"key":"13101_CR29","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1158\/1078-0432.CCR-17-2664","volume":"24","author":"MN Theodoraki","year":"2018","unstructured":"Theodoraki, M. N., Yerneni, S. S., Hoffmann, T. K., Gooding, W. E. & Whiteside, T. L. Clinical significance of PD-L1(+) exosomes in plasma of head and neck cancer patients. Clin. Cancer Res. 24, 896\u2013905. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2664 (2018).","journal-title":"Clin. Cancer Res."},{"key":"13101_CR30","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41422-018-0060-4","volume":"28","author":"Y Yang","year":"2018","unstructured":"Yang, Y. et al. Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res. 28, 862\u2013864. https:\/\/doi.org\/10.1038\/s41422-018-0060-4 (2018).","journal-title":"Cell Res."},{"key":"13101_CR31","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","volume":"177","author":"M Poggio","year":"2019","unstructured":"Poggio, M. et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell 177, 414-427 e413. https:\/\/doi.org\/10.1016\/j.cell.2019.02.016 (2019).","journal-title":"Cell"},{"key":"13101_CR32","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","volume":"560","author":"G Chen","year":"2018","unstructured":"Chen, G. et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560, 382\u2013386. https:\/\/doi.org\/10.1038\/s41586-018-0392-8 (2018).","journal-title":"Nature"},{"key":"13101_CR33","doi-asserted-by":"publisher","first-page":"1710899","DOI":"10.1080\/20013078.2019.1710899","volume":"9","author":"M Cordonnier","year":"2020","unstructured":"Cordonnier, M. et al. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients. J. Extracell. Vesicles 9, 1710899. https:\/\/doi.org\/10.1080\/20013078.2019.1710899 (2020).","journal-title":"J. Extracell. Vesicles"},{"key":"13101_CR34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12967-019-2101-2","volume":"17","author":"C Li","year":"2019","unstructured":"Li, C. et al. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. J. Transl. Med. 17, 355. https:\/\/doi.org\/10.1186\/s12967-019-2101-2 (2019).","journal-title":"J. Transl. Med."},{"key":"13101_CR35","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1111\/cas.13697","volume":"109","author":"YL Tai","year":"2018","unstructured":"Tai, Y. L., Chen, K. C., Hsieh, J. T. & Shen, T. L. Exosomes in cancer development and clinical applications. Cancer Sci. 109, 2364\u20132374. https:\/\/doi.org\/10.1111\/cas.13697 (2018).","journal-title":"Cancer Sci."},{"key":"13101_CR36","doi-asserted-by":"publisher","first-page":"10277","DOI":"10.1073\/pnas.0805458105","volume":"105","author":"KA Hofmeyer","year":"2008","unstructured":"Hofmeyer, K. A., Ray, A. & Zang, X. The contrasting role of B7\u2013H3. Proc. Natl. Acad. Sci. U. S. A. 105, 10277\u201310278. https:\/\/doi.org\/10.1073\/pnas.0805458105 (2008).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"13101_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701006","volume":"12","author":"WT Zhou","year":"2021","unstructured":"Zhou, W. T. & Jin, W. L. B7\u2013H3\/CD276: An emerging cancer immunotherapy. Front. Immunol. 12, 701006. https:\/\/doi.org\/10.3389\/fimmu.2021.701006 (2021).","journal-title":"Front. Immunol."},{"key":"13101_CR38","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3389\/fimmu.2018.00784","volume":"9","author":"S Yang","year":"2018","unstructured":"Yang, S., Wang, J., Brand, D. D. & Zheng, S. G. Role of TNF-TNF receptor 2 signal in regulatory T cells and its therapeutic implications. Front. Immunol. 9, 784. https:\/\/doi.org\/10.3389\/fimmu.2018.00784 (2018).","journal-title":"Front. Immunol."},{"key":"13101_CR39","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/eji.202048988","volume":"51","author":"O Ticha","year":"2021","unstructured":"Ticha, O. et al. TNFR2 expression is a hallmark of human memory B cells with suppressive function. Eur. J. Immunol. 51, 1195\u20131205. https:\/\/doi.org\/10.1002\/eji.202048988 (2021).","journal-title":"Eur. J. Immunol."},{"key":"13101_CR40","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.4049\/jimmunol.1102827","volume":"189","author":"G Koncz","year":"2012","unstructured":"Koncz, G. et al. Vesicles released by activated T cells induce both Fas-mediated RIP-dependent apoptotic and Fas-independent nonapoptotic cell deaths. J. Immunol. 189, 2815\u20132823. https:\/\/doi.org\/10.4049\/jimmunol.1102827 (2012).","journal-title":"J. Immunol."},{"key":"13101_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101047","volume":"14","author":"J Wang","year":"2021","unstructured":"Wang, J., Zeng, H., Zhang, H. & Han, Y. The role of exosomal PD-L1 in tumor immunotherapy. Transl. Oncol. 14, 101047. https:\/\/doi.org\/10.1016\/j.tranon.2021.101047 (2021).","journal-title":"Transl. Oncol."},{"key":"13101_CR42","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/cmi.12046","volume":"15","author":"S Columba Cabezas","year":"2013","unstructured":"Columba Cabezas, S. & Federico, M. Sequences within RNA coding for HIV-1 Gag p17 are efficiently targeted to exosomes. Cell Microbiol. 15, 412\u2013429. https:\/\/doi.org\/10.1111\/cmi.12046 (2013).","journal-title":"Cell Microbiol."},{"key":"13101_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0050158","volume":"5","author":"Y Fang","year":"2007","unstructured":"Fang, Y. et al. Higher-order oligomerization targets plasma membrane proteins and HIV gag to exosomes. PLoS Biol. 5, e158. https:\/\/doi.org\/10.1371\/journal.pbio.0050158 (2007).","journal-title":"PLoS Biol."},{"key":"13101_CR44","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1600-0854.2009.01006.x","volume":"11","author":"M Lenassi","year":"2010","unstructured":"Lenassi, M. et al. HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. Traffic 11, 110\u2013122. https:\/\/doi.org\/10.1111\/j.1600-0854.2009.01006.x (2010).","journal-title":"Traffic"},{"key":"13101_CR45","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.chom.2009.06.009","volume":"6","author":"C Muratori","year":"2009","unstructured":"Muratori, C. et al. Massive secretion by T cells is caused by HIV Nef in infected cells and by Nef transfer to bystander cells. Cell Host Microbe 6, 218\u2013230. https:\/\/doi.org\/10.1016\/j.chom.2009.06.009 (2009).","journal-title":"Cell Host Microbe"},{"key":"13101_CR46","doi-asserted-by":"publisher","first-page":"20014","DOI":"10.1074\/jbc.M112.438895","volume":"288","author":"A Narayanan","year":"2013","unstructured":"Narayanan, A. et al. Exosomes derived from HIV-1-infected cells contain trans-activation response element RNA. J. Biol. Chem. 288, 20014\u201320033. https:\/\/doi.org\/10.1074\/jbc.M112.438895 (2013).","journal-title":"J. Biol. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13101-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13101-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13101-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T03:34:57Z","timestamp":1669347297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13101-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["13101"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-13101-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"assertion":[{"value":"22 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9185"}}